Research Trials

If you have any questions or are interested in participating in one of our clinical trials, please jot down the trial number and contact your Nebraska Cancer Specialists medical oncologist or a member of our clinical research team at 402.955.2691, or email us at clinicaltrials@nebraskacancer.com.

  • Cancer Type:

  • Biomarker:

  • Phase:

  • Keyword:

  • VMT-a-NET

    Phase 1/2a first in human study of VMTaNET Targeted Alpha Particle Therapy for advanced SSTR2 Positive Neuroendocrine Tumors

    Cancer Type: Neuroendocrine, Theranostics

    Lines of Therapy: 1

    Biomarkers: SSTR2

    Phase: 1

    View Details on ClinicalTrials.gov
  • XL092-002 (STELLAR 002)

    Study of XL092 in Combination With Immuno-Oncology Agents in Subjects With Solid Tumors (STELLAR-002)

    Cancer Type: Renal

    Phase: 1b

    View Details on ClinicalTrials.gov
  • SLC-391-102, Skylite

    Phase 1b/2 study of SLC-391, an AXL inhibitor, in ccombination with pembrolizumab in subjects wiht advanced or meastatic NSCLC

    Cancer Type: Lung NSCLC

    Lines of Therapy: 3, 2, 1

    Biomarkers: PD-L1+

    Phase: 2

    View Details on ClinicalTrials.gov
  • RYZ101-101

    Phase 1b single arm, open-label trial of RYZ101 in combination with carboplatin + etoposide + atezolizumab in subjects with somatostatin receptor expressing (SSTR+) extensive stage small cell lung cancer (ES-SCLC)

    Cancer Type: Lung SCLC

    Lines of Therapy: 1

    Biomarkers: SSTR+

    Phase: 1

    View Details on ClinicalTrials.gov
  • Teligene (TL-EGFR-2201)

    A phase 2 study to evaluate the efficacy and safety of Sutetinib Maleate Capsule in locally advanced or metastatic NSCLC

    Cancer Type: Lung NSCLC

    Lines of Therapy: 2

    Phase: 2

    View Details on ClinicalTrials.gov
  • SIBYL, 06-MX-001, PLP-002043-R2

    Observational study of therapy response with liquid biopsy evaluation.

    Cancer Type: BREAST, Colorectal

    Lines of Therapy: 2, 1

    Phase: Observational

    View Details on ClinicalTrials.gov
  • VM Oncology, VMO-01C

    Open label, multidose, dose escalation study to investigate the safety, pharmokinetics, and pharmacodynamics of VMC 928 in subjects with solid tumors or lymphoma

    Cancer Type: Solid tumor, Lymphoma

    Biomarkers: TrkA

    Phase: 1

    View Details on ClinicalTrials.gov
  • TPX-0005-07

    A Phase 1/2, Open-label, safety, tolerability, pharmacokinetics, and anti-tumor activity study of repotrectinib in pediatric and young adult subjects with advances or metastatic malignancies harboring ALK, ROS1, or NTRK1-3 alterations

    Cancer Type: Solid tumor

    Biomarkers: ALK, ROS1, NTRK1-3

    Phase: 2

    View Details on ClinicalTrials.gov
  • Teligene (SZCT-2020-06)

    A Phase 2b study to evaluate the efficacy and safety of sutetinib maleate capsule in locally advanced or metastatic NSCLC (non-resistant uncommon EGFR mutations only, including L861Q, G719X, and/or S768I)

    Cancer Type: Lung NSCLC

    Lines of Therapy: 2

    Phase: 2b

    View Details on ClinicalTrials.gov
  • RYZBIO-801

    Phase 1/1b single arm, open-label trial of theranostic pair RYZ811 (diagnostic) and RYZ801 (therapeutic to identify and treat subjects with GPC3 positive unresectable hepatocellular carinoma (HCC)

    Cancer Type: hepatocellular, Theranostics

    Biomarkers: GPC3

    Phase: 1

#caringforthegoodlife

Meet DOT.

Skip to content